Skip to main content

MS news

Our news web pages include ground-breaking multiple sclerosis news and research from around the world. 

These news stories are taken from external sources and as such, MS-UK does not verify, endorse or accept responsibility for their content.

Some of these pages have been written for medical professionals and this can be reflected in the complexity of language and content. If you have any issues relating to the topics here, please call the MS-UK Helpline on 0800 7830 518.


 

Patients with multiple sclerosis (MS) taking Ocrelizumab are more likely to achieve no evidence of disease activity (NEDA) than those taking beta interferon, researchers from the pivotal OPERA I...

Aubagio is associated with reduced risk of disability progression among patients experiencing multiple sclerosis (MS) relapse, compared to placebo, according to a post-hoc analysis of clinical...

Aubagio treatment decreased brain volume loss in patients with relapsing-remitting multiple sclerosis (MS) independent of disability progression, a study presented at the 68th annual American...

Intrathecal administration of autologous mesenchymal stem cell-derived neural progenitors (MSC-NPs) was safe and well tolerated as a regenerative multiple sclerosis (MS) therapy, concluded a first...

Delayed-release dimethyl fumarate (DMF) has been associated with significant reductions in confirmed disability progression (CDP) in patients newly diagnosed with relapsing-remitting multiple...

Patients with relapsing-remitting multiple sclerosis (MS) treated with daclizumab high-yield process (HYP) had improved cognitive outcomes at 96 weeks compared with beta interferon, a study...

No correlation between interferon treatment and antidepressant use has been observed in the multiple sclerosis (MS) population, a large-scale study presented at the 68th AAN Annual Meeting...

Regardless of whether the disease is in the progressive phase or not, patients with multiple sclerosis (MS) seem likely to experience relapses for the first time or relapse continuation between...

The effects of Cladribine for relapsing-remitting multiple sclerosis (RRMS) patients have been demonstrated to last for up to four years after treatment has started, according to the findings of a...

Arbaclofen extended-release tablets (AERT) have proved to have greater tolerability, and similar efficacy and safety, to baclofen in patients with multiple sclerosis (MS), according to randomised...

Pages

Live Chat Software by Click4Assistance UK